Sertindole: An atypical antipsychotic for the treatment of schizophrenia

Formulary

Volumn 32, Issue 9, 1997, Pages 907-925

  Cardoni, Alex A ^a,b   Myer, Shivani ^b,c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b INSTITUTE OF LIVING   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CIMETIDINE; CLOZAPINE; CYTOCHROME P450; ERYTHROMYCIN; FLUOXETINE; ITRACONAZOLE; KETOCONAZOLE; OLANZAPINE; PAROXETINE; PHENYTOIN; QUINIDINE; RISPERIDONE; SERTINDOLE;

AKATHISIA; AMBLYOPIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; META ANALYSIS; MUSCLE HYPERTONIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PSYCHOSIS; QT INTERVAL; RATING SCALE; REVIEW; RHINITIS; TOBACCO;

EID: 0030758887     PISSN: 00986909     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Sanchez C, Arnt J, Dragsted N, et al. Neurochemical and in vivo pharmacological profile of sertindole: A limbic-selective neuroleptic compound. Drug Develop Res 1991;22:239-50.
2. Casey DE. Side effect profiles of new antipsychotic agents. J Clin Psychiatry 1996;57(Suppl 11):40-5.
3. van Kammen DP, McEvoy JP, Targum SD, et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacol 1996;124:168-75.
4. Skarsfeldt T, Perregaard J. Sertindole, a new neuroleptic with extreme selectivity on A10 versus A9 dopamine neurons in the rat. Eur J Pharmacol 1990; 182:613-4.
5. 1 receptors. J Neural Transm 1992;89:61-9.
6. Casey DE. Behavioral effects of sertindole, risperidone, clozapine, and haloperidol in Cebus monkeys. Psychopharmacol 1996;124:134-40.
7. Casey DE. Sertindole: The rational design of a selective antipsychotic drug. Presented at the Serlect (Sertindole) Investigator Meeting Phase III Results. March 9, 1996, North Chicago, IL.
8. Sanchez C, Arnt J, Costall B, et al. Sertindole - A limbic-selective neuroleptic with potent anxiolytic effects. Soc Neurosci Abs 1992;18:549.
9. Potkin S, Zborowski J, et al. Brain imaging to determine the effects of sertindole in schizophrenic patients, (abstract) Biol Psychiatry 1996;39:514.
10. Ereshefsky L. Pharmacokinetics and drug interactions: Update for new antipsychotics. J Clin Psychiatry 1996; 57(Suppl 11):12-25.
11. Green B. Focus on Sertindole. Psychiatry On Line, Priory Lodge Education, Ltd. September 1996.
12. Menacherry SD, Stamm GE. Analytic method for sertindole and its metabolites in human serum and rat, dog, and mouse plasma. Sertindole Annotated Bibliography - In Vitro and Ex Vivo Studies, Abbott Laboratories, April 1996.
13. Mulford DJ. Metabolism of sertindole: Metabolite identification and comparison in rat, mouse, dog, monkey rabbit, and human hepatic microsomes. Sertindole Annotated Bibliography - In Vitro and Ex Vivo studies, Abbott Laboratories, April, 1996.
14. Granneman GR, Wozniak P, Ereshefsky L, et al. Population pharmacokinetics of sertindole during long-term treatment of patients with schizophrenia. Poster presentation, Annual Meeting of the American College of Neuropsychopharmacology, December 1996, Puerto Rico.
15. Friberg HH, Skarsfeldt T, Pierce M, et al. Sertindole, a novel atypical neuroleptic drug candidate - safety and tolerance in normal human subjects. (abstract) Schizophr Res 1992;6:111-2.
16. McEvoy J, Borison R, Small J, et al. The efficacy and tolerability of sertindole in schizophrenic patients: A pilot, double-blind, placebo-controlled, dose-ranging study. (abstract) Schizophr Res 1993;9: 244.
17. Martin PT, Grebb JA, Schmitz PJ, et al. Efficacy and safety of sertindole in double-blind, placebo-controlled trials of schizophrenic patients, (abstract) Schizophr Res 1994;11:107.
18. Zimbroff DL, Kane JM, Taminga CA, et al. A controlled, dose-response study of sertindole and haloperidol in schizophrenia. Am J Psychiatry 1997;54:782-91.
19. Potkin SG, Targum SD, et al. Comparative efficacy and safety of sertindole and haloperidol in patients with schizophrenia. Sertindole Annotated Bibliography - Clinical Studies, Abbott Laboratories, April 1996.
20. Krystal J, D'Souza DC, Holgate KL, et al. Sertindole: A multi-center, one-year, haloperidol-controlled trial assessing the long-term safety, efficacy, and quality of life in stable schizophrenic patients. Poster Presentation, Annual Meeting of the American College of Neuropsychopharmacology, December 1996, Puerto Rico.
21. Jibson MD, Tandon R. A summary of research findings on the new antipsychotic drugs. Essent Psychopharmacol 1996;1:33-4.
22. Data on File, Abbott Laboratories, 1996.
23. Carlson D. Personal communication, Abbott Laboratories, April 1997.
24. Swann A, Daniel D, Silber C, Mack R. Long term cardiovascular safety of sertindole. Poster presentation at the Annual Meeting of the American College of Neuropsychopharmacology, December 1996, Puerto Rico.
25. Mack R. Personal communication, Abbott Laboratories, April 1997.
26. Pratt CM, Pritchett ELC, Roden DM. Cardiovascular safety of sertindole. Report submitted to Abbott Laboratories, June 24, 1996.
27. Barnett AA. Safety concerns over antipsychotic drug, sertindole. The Lancet 1996;348:256.
28. Lundbeck H. Summary of product characteristics, serdolect (sertindole). Final MRP SPC, United Kingdom, October 1996.
29. Ames D, Wirshing W, Marder S. Advances in antipsychotic pharmacotherapy: Clozapine, risperidone, and beyond. Essent Psychopharmacol 1996; 1:5-26.
30. Tamminga CA. Brain Mechanisms of Antipsychotic Drug Action, presented at the Annual Meeting of American Psychiatric Association, May 7, 1996, New York, NY.